Epctu
Ended Awarded Last action
- Contract number
- 75N93023F00001
- Awardee
-
PPD Development LP UEI ZANENSW6C665
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,791,811
Award facts
- Contract value 100% obligated
- $2,791,811.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Cape Fear, NC 28401, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $2,687,546 | |
| Original award | $104,265 |
About this award
PPD Development LP, a global contract research organization and subsidiary of Thermo Fisher Scientific, was awarded a delivery order valued at $2.79M by the National Institute of Allergy and Infectious Diseases (NIAID) on June 29, 2023. This task order falls under the Early Phase Clinical Trial Units (EPCTU) Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle, which represents a $346M master agreement designed to support early-stage clinical research across multiple therapeutic areas. The delivery order requires PPD Development LP to implement Phase 0 through Phase II clinical trials, including proof-of-concept studies in both healthy and diseased human populations, with execution occurring domestically and internationally, supplemented by bioanalysis services as needed. The contract specifies potential Phase III study activities and carries a ceiling value of approximately $2.79M with an ultimate completion date of January 31, 2026.
The work will be performed at PPD Development LP's facility in Cape Fear, North Carolina. This award reflects NIAID's continued reliance on PPD Development LP's expertise in clinical trial management and regulatory support, leveraging the contractor's extensive experience in infectious disease research and federal clinical research coordination. The contract utilizes a cost-plus-fixed-fee pricing structure without any small business set-aside designation, representing a continuation of PPD Development LP's substantial role in supporting the federal government's clinical research infrastructure through both the EPCTU vehicle and other major IDIQs spanning agencies including the National Institutes of Health, Department of Defense, and National Cancer Institute.
Quick answers
Who was awarded contract 75N93023F00001?
75N93023F00001 was awarded to PPD Development LP by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 29, 2023.
How much is contract 75N93023F00001 worth?
The government has obligated $2,791,811 on 75N93023F00001.
Is contract 75N93023F00001 an order under another contract?
Yes. 75N93023F00001 is a delivery order under 75N93022D00017, an indefinite delivery contract, on Early Phase Clinical Trial Units (EPCTU).
Was contract 75N93023F00001 competed?
The extent of competition for 75N93023F00001 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award